JP2008529502A - 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 - Google Patents

細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 Download PDF

Info

Publication number
JP2008529502A
JP2008529502A JP2007554337A JP2007554337A JP2008529502A JP 2008529502 A JP2008529502 A JP 2008529502A JP 2007554337 A JP2007554337 A JP 2007554337A JP 2007554337 A JP2007554337 A JP 2007554337A JP 2008529502 A JP2008529502 A JP 2008529502A
Authority
JP
Japan
Prior art keywords
cell
nicotinamide
cells
sir2
nad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007554337A
Other languages
English (en)
Japanese (ja)
Inventor
デイビッド， エー． シンクレア，
ケビン， ジェイ． ビターマン，
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2008529502A publication Critical patent/JP2008529502A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2007554337A 2005-02-08 2006-02-08 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 Pending JP2008529502A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/053,185 US7977049B2 (en) 2002-08-09 2005-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
PCT/US2006/004397 WO2006086454A2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012104652A Division JP2012176962A (ja) 2005-02-08 2012-05-01 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物

Publications (1)

Publication Number Publication Date
JP2008529502A true JP2008529502A (ja) 2008-08-07

Family

ID=36591266

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007554337A Pending JP2008529502A (ja) 2005-02-08 2006-02-08 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物
JP2012104652A Pending JP2012176962A (ja) 2005-02-08 2012-05-01 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物
JP2015098029A Pending JP2015180657A (ja) 2005-02-08 2015-05-13 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012104652A Pending JP2012176962A (ja) 2005-02-08 2012-05-01 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物
JP2015098029A Pending JP2015180657A (ja) 2005-02-08 2015-05-13 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物

Country Status (7)

Country Link
US (2) US7977049B2 (https=)
EP (1) EP1851240B1 (https=)
JP (3) JP2008529502A (https=)
AU (1) AU2006212770B2 (https=)
CA (1) CA2595495C (https=)
ES (1) ES2401342T3 (https=)
WO (1) WO2006086454A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
JP2018515487A (ja) * 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
JP2022544776A (ja) * 2019-08-14 2022-10-21 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421269A1 (en) * 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20090117543A1 (en) * 2004-05-04 2009-05-07 President And Fellows Of Harvard College Methods and compositions for inducing sirtuins
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
PL1794306T3 (pl) * 2004-09-24 2010-05-31 Bayer Cropscience Nv Rośliny oporne na stres
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2007084162A2 (en) * 2005-04-08 2007-07-26 President And Fellows Of Harvard College Sirtuin inhibiting compounds
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP3369738B1 (en) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
US8158856B2 (en) * 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
AU2008210327B2 (en) * 2007-01-31 2011-06-16 Methylation Sciences International Srl Extended release pharmaceutical formulations of S-adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008095056A2 (en) * 2007-02-01 2008-08-07 The Wistar Institute Method for identifying a compound that modulates sir2 protein activity
WO2009054994A2 (en) * 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
EP2222833A4 (en) * 2007-11-30 2011-05-18 Univ California Industrial production of organic compounds using recombinant organisms expressing methyl halide transferase
JP5570731B2 (ja) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 ピロリン酸の測定方法
AU2009322474A1 (en) * 2008-12-01 2011-07-21 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2385829B1 (en) 2009-01-09 2018-08-01 Board of Regents of the University of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2805041A1 (en) 2009-07-22 2011-01-27 The Regents Of The University Of California Cell-based systems for production of methyl formate
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
GB201007197D0 (en) * 2010-04-30 2010-06-16 Ge Healthcare Uk Ltd Methods and kits for determining the toxicity of an agent
WO2012068463A2 (en) * 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP3345901A3 (en) * 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
WO2014059031A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
ES2540581T3 (es) 2012-10-17 2015-07-10 Methylation Sciences International Srl Composiciones que comprenden S-adenosilmetionina y un éster de ácido gálico
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US10513706B2 (en) 2014-04-09 2019-12-24 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US9995758B1 (en) 2014-10-31 2018-06-12 Western Autotroph Company LLC Methods and systems for controlling oxidative stress in humans and animals
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
CA2984379C (en) 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2016178944A1 (en) 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3236928B1 (en) 2016-01-11 2020-12-09 The Procter and Gamble Company Method of treating a skin condition and compositions therefor
CA3020728A1 (en) 2016-03-31 2017-10-05 Berkeley Lights, Inc. Nucleic acid stabilization reagent, kits, and methods of use thereof
MX393076B (es) 2016-04-20 2025-03-24 Chromadex Inc Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
WO2018129039A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
US11491175B2 (en) 2019-02-25 2022-11-08 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
CN111394268B (zh) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 基因工程菌及其构建方法、应用，生产nad+的方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
AU2021322286A1 (en) * 2020-08-07 2023-04-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Single nucleotide polymorphisms and treatment of inflammatory conditions
AU2022281388A1 (en) 2021-05-27 2023-12-07 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
WO2023086770A1 (en) * 2021-11-10 2023-05-19 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection gene therapy
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
AU2024274445A1 (en) 2023-05-15 2025-11-27 Bonafide Health, Llc Sleep-improving compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179937A (en) 1978-06-02 1979-12-25 Ocean Ecology Ltd. Sound measuring device
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63152309A (ja) * 1986-08-11 1988-06-24 Lion Corp 皮膚外用剤
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5689046A (en) 1987-09-30 1997-11-18 Bayer Aktiengesellschaft Stilbene synthase gene
DE3733017A1 (de) 1987-09-30 1989-04-13 Bayer Ag Stilbensynthase-gen
EP0331620B1 (de) * 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE4107396A1 (de) * 1990-06-29 1992-01-02 Bayer Ag Stilbensynthase-gene aus weinrebe
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
JP3214049B2 (ja) 1992-03-09 2001-10-02 史衛 佐藤 シス−オレフィンの製造法
DE4232899C2 (de) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
DE4440200A1 (de) * 1994-11-10 1996-05-15 Bayer Ag DNA-Sequenzen und ihre Verwendung
NZ300387A (en) 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
DK0811073T3 (da) 1995-02-24 2007-05-21 Univ Pennsylvania Avendelse af immunmodulatorer til fremstilling af medikamenter til inhibering af immunresponser mod co-administrerede rekombinanter
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
FR2741238B1 (fr) * 1995-11-17 2001-11-30 Goemar Lab Sa Utilisation du chlorure d'aluminium comme agent eliciteur de la synthese du resveratrol
US6124125A (en) * 1996-01-08 2000-09-26 Trustees Of Dartmouth College AMP activated protein kinase
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
FR2766176B1 (fr) * 1997-07-15 1999-10-29 Caudalie Compositions a base de derives de resveratrol
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
BR9803596A (pt) * 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6008260A (en) 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US6624197B1 (en) * 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6245814B1 (en) * 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
ES2258337T3 (es) 1998-09-08 2006-08-16 Cornell Research Foundation, Inc. Uso de inhibidores de la ciclooxigenasa-2 para el tratamiento de enfermedades inflamatorias de cabeza y cuello.
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US6361815B1 (en) * 1998-12-21 2002-03-26 Pure World Botanicals, Inc. Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
US6190716B1 (en) * 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
US6878381B2 (en) 1999-03-22 2005-04-12 Pfizer, Inc Resorcinol composition
ATE365326T1 (de) * 1999-04-12 2007-07-15 Sumitomo Chemical Co Verfahren zur analyse der menge an intraabdominalem fettgewebe
FR2795643B1 (fr) 1999-07-02 2004-06-11 Oreal Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique
DE60015568D1 (de) 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
HK1047889B (en) * 1999-09-03 2009-04-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU7596100A (en) * 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6358517B1 (en) * 1999-10-22 2002-03-19 Unilever Home & Personal Care Usa, Division Of Conopco Cosmetic compositions containing resveratrol and retinoids
US20020002200A1 (en) 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6416806B1 (en) * 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
WO2001070212A2 (en) 2000-03-23 2001-09-27 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of menopause
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
IT1317034B1 (it) 2000-05-30 2003-05-26 Istituto Di Medicina Speriment Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
ITNA20000036A1 (it) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se Nuovi approcci terapeutici per il trattamento della forfora.
ITNA20000037A1 (it) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se Filtro solare multifunzione innovativo.
IT1318565B1 (it) 2000-06-09 2003-08-27 World Pharma Tech Ltd Integratore alimentare proenergetico a base di nadh octocosanolo evitamina e.
US6795856B1 (en) 2000-06-28 2004-09-21 Accountability International, Inc. System and method for monitoring the internet access of a computer
US6319523B1 (en) 2000-06-29 2001-11-20 James H. Zhou Composition and method for inhibiting oral bacteria
US20020120008A1 (en) * 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
DE10034320A1 (de) * 2000-07-14 2002-02-07 Inst Pflanzenbiochemie Ipb Verfahren zur Beeinflussung des Sinapingehalts in transgenen Pflanzenzellen und Pflanzen
FR2812195B1 (fr) * 2000-07-28 2003-07-11 Oreal Compositions a application topique comprenant des hydroxystilbenes glucosyles et utilations
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US6541522B2 (en) * 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US6552085B2 (en) * 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
WO2002039956A2 (en) * 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US20030165854A1 (en) * 2000-12-05 2003-09-04 Cunningham Mary Jane Marker genes responding to treatment with toxins
US20030082647A1 (en) * 2000-12-12 2003-05-01 Reenan Robert A. Transporter protein
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
WO2002056823A2 (en) 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US20030190381A1 (en) 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
FR2820320B1 (fr) * 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
WO2002081651A2 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
US6300377B1 (en) * 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
ITPI20010014A1 (it) * 2001-03-05 2002-09-05 Ivo Pera Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US20030044946A1 (en) * 2001-04-03 2003-03-06 Longo Valter D. Genes, mutations, and drugs that increase cellular resistance to damage and extend longevity in organisms from yeast to humans
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US20030180719A1 (en) * 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6426061B1 (en) * 2001-04-20 2002-07-30 Weiwei Li Method and composition for preventing sweat-related odor
ATE466577T1 (de) 2001-05-03 2010-05-15 Cornell Res Foundation Inc Behandlung von krankheiten, die durch hpv verursacht werden
US6368617B1 (en) * 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
EP1532244A4 (en) * 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
US7241743B2 (en) * 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
US7384920B2 (en) 2001-07-26 2008-06-10 Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
US7396546B2 (en) 2001-08-06 2008-07-08 The Quigley Corporation Anti-microbial compositions and methods of using same
CA2457370A1 (en) * 2001-08-15 2003-02-27 Elixir Pharmaceuticals, Inc. Age-associated markers
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
US20030055114A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6680342B2 (en) * 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6656969B2 (en) * 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
BR0212897A (pt) * 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
US20030082116A1 (en) * 2001-09-28 2003-05-01 Closure Medical Corporation Adhesive compositions containing dual function stabilizers and active agents
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
EP1304161B1 (en) * 2001-10-19 2007-02-28 Pacific Corporation Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
EP1304048B1 (en) * 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
US6767563B2 (en) * 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
CN1310937C (zh) * 2001-11-21 2007-04-18 犹太大学阿尔伯特爱因斯坦医学院 Sir2产物及活性
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition
FR2832630B1 (fr) * 2001-11-28 2005-01-14 Oreal Composition cosmetique et/ou dermatologique contenant au moins un actif hydrophile sensible a l'oxydation stabilise par au moins un copolymere de n-vinylimidazole
US20030118617A1 (en) * 2001-12-21 2003-06-26 Avon Products, Inc. Resveratrol analogues
NZ516366A (en) * 2001-12-24 2004-07-30 Enzo Nutraceuticals Ltd Increased lifespan formulation using pine bark flavonoid extract
AU2002367363A1 (en) * 2001-12-26 2003-07-24 The Regents Of The University Of California System and method for identifying networks of ternary relationships in complex data systems
AU2003210477A1 (en) * 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
ATE555782T1 (de) 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
US20030199581A1 (en) 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
EP1381619B1 (en) 2002-03-28 2005-01-12 Council of Scientific and Industrial Research 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, process of isolation from pterocarpus marsupium and pharmaceutical composition for treatment of diabetes
US20030224077A1 (en) 2002-04-08 2003-12-04 Societe L'oreal S.A. Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
WO2003094833A2 (en) * 2002-05-10 2003-11-20 Orchid Chemicals & Pharmaceuticals Limited A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene
AU2003238899A1 (en) 2002-06-07 2003-12-22 Wisconsin Alumni Research Foundation Method of controling acetylation of metabolic enzymes
WO2003103583A2 (en) 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
DE10230961A1 (de) 2002-07-10 2004-02-12 Lorenz, Peter, Dr. Verwendung von Oxyresveratrol als Neuroprotektivum
AU2003242965B2 (en) * 2002-07-11 2009-02-05 Dermipsor Ltd. Composition and methods for the treatment of skin disorders
WO2004009539A2 (en) 2002-07-19 2004-01-29 Orchid Chemicals And Pharmaceuticals Limited Method for the conversion of a z-isomer into e-isomer
DE10244282A1 (de) 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
EP2218342B1 (en) 2003-05-27 2018-07-04 DSM IP Assets B.V. Novel nutraceutical compositions and use thereof
CA2529510A1 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US20050004052A1 (en) * 2003-07-03 2005-01-06 Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
US20050038125A1 (en) * 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
CA2538759C (en) 2003-09-12 2015-11-03 Elixir Pharmaceuticals, Inc. Substituted heterocyclic compounds as sirtuin inhitibitors
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
ES2301898T3 (es) * 2004-06-03 2008-07-01 Balcke-Durr Gmbh Procedimiento y dispositivo para ensanchamiento hidraulico.
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
PL1794306T3 (pl) 2004-09-24 2010-05-31 Bayer Cropscience Nv Rośliny oporne na stres
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US8158856B2 (en) 2006-03-21 2012-04-17 Bayer Cropscience Nv Stress resistant plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
CN109985056A (zh) * 2013-10-30 2019-07-09 可劳迈戴斯有限公司 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
US10688118B2 (en) 2013-10-30 2020-06-23 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
US11033568B2 (en) 2013-10-30 2021-06-15 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
JP2018515487A (ja) * 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
JP2022544776A (ja) * 2019-08-14 2022-10-21 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物
JP7702934B2 (ja) 2019-08-14 2025-07-04 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物

Also Published As

Publication number Publication date
ES2401342T3 (es) 2013-04-18
CA2595495C (en) 2014-12-09
EP1851240B1 (en) 2012-12-12
AU2006212770B2 (en) 2013-04-04
US20050267023A1 (en) 2005-12-01
JP2015180657A (ja) 2015-10-15
JP2012176962A (ja) 2012-09-13
WO2006086454A3 (en) 2007-03-29
WO2006086454A2 (en) 2006-08-17
AU2006212770A1 (en) 2006-08-17
CA2595495A1 (en) 2006-08-17
EP1851240A2 (en) 2007-11-07
US7977049B2 (en) 2011-07-12
US20120022013A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
US7977049B2 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP6602561B2 (ja) 細胞及び生物の寿命を延ばし、ストレス耐性を増す方法及び組成物
Kuo et al. Polycystin 2 regulates mitochondrial Ca2+ signaling, bioenergetics, and dynamics through mitofusin 2
Boyault et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
Woodgett Judging a protein by more than its name: GSK-3
Eizirik et al. The role for endoplasmic reticulum stress in diabetes mellitus
Elrick et al. Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1
Yu et al. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines
Hu et al. 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling
Grigorieva et al. Transcription factors in parathyroid development: lessons from hypoparathyroid disorders
Li Iron pathophysiology in Friedreich’s ataxia
US8546074B2 (en) Sir2 activity
Su et al. Oxidative stress induces neuronal apoptosis through suppressing transcription factor EB phosphorylation at Ser467
Price et al. Cell cycle regulation: repair and regeneration in acute renal failure
AU2002320325B2 (en) SIR2 activity
AU2002320325A1 (en) SIR2 activity
AU2013206647A1 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
Zhang The Effect of Transcription Factor Zhangfei/CREBZF on Osteosarcoma Cells and the Mechanisms Responsible
CA2519161A1 (en) Sir2 activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120229

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120717